Literature DB >> 20018628

PDCA expression by B lymphocytes reveals important functional attributes.

Dass S Vinay1, Chang H Kim, Kyung H Chang, Byoung S Kwon.   

Abstract

We have demonstrated in this study the existence of a PDCA-expressing functional B cell population (PDCA+ B lymphocytes), which differentiates from activated conventional B (PDCA-IgM+) lymphocytes. Stimulation with anti-micro, LPS, CpG oligodeoxynucleotide, HSV-1, or CTLA-4 Ig activates the PDCA+ B lymphocytes, leading to cell division and induction of type I IFNs and IDO. Notably, the PDCA+ B lymphocytes are capable of Ag-specific Ab production and Ig class switching, which is corroborated by transfer experiments in B- and PDCA+ B lymphocyte-deficient microMT mice. Importantly, in lupus-prone MRL-Fas(lpr) mice, PDCA+ B lymphocytes remain the principal source of autoantibodies. The PDCA+ B lymphocytes have phenotypes with plasmacytoid dendritic cells, but are a distinct cell population in that they develop from C-kit+B220+ pro-B precursors. Thus, our data suggest that not all PDCA+ cells are dendritic cell-derived plasmacytoid dendritic cells and that a significant majority is the PDCA+ B lymphocyte population having distinct phenotype and function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018628     DOI: 10.4049/jimmunol.0902528

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Resident plasmacytoid dendritic cells patrol vessels in the naïve limbus and conjunctiva.

Authors:  Arsia Jamali; Deshea L Harris; Tomas Blanco; Maria J Lopez; Pedram Hamrah
Journal:  Ocul Surf       Date:  2020-02-25       Impact factor: 5.033

2.  B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase.

Authors:  Burles A Johnson; David J Kahler; Babak Baban; Phillip R Chandler; Baolin Kang; Michiko Shimoda; Pandelakis A Koni; Jeanene Pihkala; Bojan Vilagos; Meinrad Busslinger; David H Munn; Andrew L Mellor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

3.  Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Authors:  Nicholas M Provine; Rafael A Larocca; Pablo Penaloza-MacMaster; Erica N Borducchi; Anna McNally; Lily R Parenteau; David R Kaufman; Dan H Barouch
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

Review 4.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

5.  A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo.

Authors:  Bradley S Barrett; Diana S Smith; Sam X Li; Kejun Guo; Kim J Hasenkrug; Mario L Santiago
Journal:  PLoS Pathog       Date:  2012-03-22       Impact factor: 6.823

Review 6.  Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.

Authors:  Soledad Mac Keon; María Sol Ruiz; Silvina Gazzaniga; Rosa Wainstok
Journal:  Front Immunol       Date:  2015-05-20       Impact factor: 7.561

7.  Infection-Induced Resistance to Experimental Cerebral Malaria Is Dependent Upon Secreted Antibody-Mediated Inhibition of Pathogenic CD8+ T Cell Responses.

Authors:  Tovah N Shaw; Colette A Inkson; Ana Villegas-Mendez; David J Pattinson; Patrick Strangward; Kathryn J Else; Simon J Draper; Leo A H Zeef; Kevin N Couper
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

Review 8.  Plasmacytoid dendritic cells in the eye.

Authors:  Arsia Jamali; Brendan Kenyon; Gustavo Ortiz; Abdo Abou-Slaybi; Victor G Sendra; Deshea L Harris; Pedram Hamrah
Journal:  Prog Retin Eye Res       Date:  2020-07-24       Impact factor: 21.198

9.  Exposure of a distinct PDCA-1+ (CD317) B cell population to agonistic anti-4-1BB (CD137) inhibits T and B cell responses both in vitro and in vivo.

Authors:  Dass S Vinay; Seung J Lee; Chang H Kim; Ho Sik Oh; Byoung S Kwon
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.